CHNC China Infrastructure Construct

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassification

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassification

HOUSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CBIH is proud to announce that Brian Cuban, Esq., a distinguished attorney, best-selling author, mental health advocate, and esteemed member of our Advisory Board, has officially joined the Reclassification Team. Mr. Cuban will play a crucial role in representing CBIH at the upcoming DEA hearings on marijuana rescheduling.

Brian Cuban, the younger brother of entrepreneur Mark Cuban, brings a unique combination of personal recovery experience and professional advocacy to the effort. A graduate of Penn State University and The University of Pittsburgh School of Law, Mr. Cuban has been a vocal champion for individuals battling addiction, mental health challenges, and societal stigma.

Mr. Cuban has established himself as a thought leader in the mental health space, authoring the best-selling book The Addicted Lawyer: Tales of The Bar, Booze, Blow & Redemption and captivating audiences across North America as a keynote speaker. His work has been featured in esteemed publications such as The New York Times, CNN.com, and The Huffington Post. His most recent release, Body Brokers, sheds light on the dark and exploitative practices within the addiction recovery industry, exposing unethical behaviors that prey on vulnerable individuals seeking treatment.

“Mr. Brian Cuban’s addition to our team reinforces our commitment to advancing reclassification,” said Rosangel Andrades, CBIH R&D Director. “I am incredibly proud to be part of a company that spares no effort or resources in taking our projects to the next level. This effort is not just about science, it’s about making a meaningful difference in the quality of life for thousands of patients.”

In addition to his advocacy, Mr. Cuban’s extensive legal background makes him a key asset in CBIH’s reclassification efforts. With over two decades of legal experience, he possesses a profound understanding of regulatory frameworks and the nuanced intersections of public policy, healthcare, and legal reform. His skill in constructing evidence-based, persuasive arguments will fortify CBIH’s case for rescheduling marijuana, helping to dismantle outdated policies that hinder scientific advancement and access to critical treatments.

The reclassification of marijuana under the Controlled Substances Act (CSA) seeks to address its current designation as a Schedule I substance, a category reserved for drugs with high abuse potential, no accepted medical use, and a lack of safety under medical supervision. This classification contradicts modern scientific and medical understanding. CBIH is committed to presenting robust scientific evidence highlighting marijuana’s proven medical benefits for conditions such as chronic pain, cancer, epilepsy, PTSD, anxiety, and more. The push for reclassification centers on advancing science, modernizing policy, and improving public health to ensure greater access to evidence-based therapies.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at

For more information contact us at:

(214) 733-0868



Dante Picazo

CEO - CBIH

Website:

X: /cbihstock

Instagram: /CBIHSTOCK



EN
13/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on China Infrastructure Construct

 PRESS RELEASE

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr....

Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today the launch of its Evidence Sprint 2026, an intensive execution phase designed to turn cannabinoid science into usable medical evidence: protocols, operational collaboration, and projects ready for competitive funding.CBIH confirms receipt of a communication from the Centers for Medicare & Medicaid Services (CMS) acknowledging Company's meeting request with CMS Administrator Dr. Mehmet Oz a...

 PRESS RELEASE

CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accele...

Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Executive Order directed the U.S. Attorney General to take necessary steps to complete the rulemaking process related to resche...

 PRESS RELEASE

CBIH Announces New Patent Initiative Targeting Opioid Addiction Throug...

Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States.According to U.S. public health data, more than 700,000 people have died from opioid-involved overdoses since the early 2000s. Despite recent progress, the crisis remains severe: in 2024 alone, a...

 PRESS RELEASE

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Op...

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate.After eighteen years of navigating scientific challenges, market volatility, stigma, and regulatory uncertainty, CBIH stated that this turn...

 PRESS RELEASE

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassific...

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassification HOUSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CBIH is proud to announce that Brian Cuban, Esq., a distinguished attorney, best-selling author, mental health advocate, and esteemed member of our Advisory Board, has officially joined the Reclassification Team. Mr. Cuban will play a crucial role in representing CBIH at the upcoming DEA hearings on marijuana rescheduling. Brian Cuban, the younger brother of entrepreneur Mark Cuban, brings a unique combination of personal recovery experience and professional advocacy to ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch